
    
      This is an open-label, dose escalation and dose expansion, study in adult participants with
      open-angle glaucoma or ocular hypertension. The study is divided into 2 parts:

      Part 1 of the study is a dose escalation, sequentially testing 3 doses of JV-GL1: low, medium
      and high.

      Part 2 of the study will be randomized 2:2:1 (Experimental Dose A: Experimental Dose B:
      Active Control), treating additional subjects at the selected JV-GL1 doses or Latanoprost for
      28 days.
    
  